期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease 被引量:8
1
作者 Shu Dong Zong-Ying Zhan +6 位作者 Hong-Yan Cao Chao Wu yan-qin bian Jian-Yuan Li Gen-Hong Cheng Ping Liu Ming-Yu Sun 《World Journal of Gastroenterology》 SCIE CAS 2017年第15期2771-2784,共14页
AIM To identify a panel of biomarkers that can distinguish between non-alcoholic fatty liver disease(NAFLD) and non-alcoholic steatohepatitis(NASH), and explore molecular mechanism involved in the process of developin... AIM To identify a panel of biomarkers that can distinguish between non-alcoholic fatty liver disease(NAFLD) and non-alcoholic steatohepatitis(NASH), and explore molecular mechanism involved in the process of developing NASH from NAFLD.METHODS Biomarkers may differ during stages of NAFLD. Urine and blood were obtained from non-diabetic subjects with NAFLD and steatosis, with normal liver function(n = 33), from patients with NASH, with abnormal liver function(n = 45), and from healthy age and sex-matched controls(n = 30). Samples were subjected to metabolomic analysis to identify potential non-invasive biomarkers. Differences in urinary metabolic profiles were analyzed using liquid chromatography tandem mass spectrometry with principal component analysis and partial least squares-discriminate analysis.RESULTS Compared with NAFLD patients, patients with NASH had abnormal liver function and high serum lipid concentrations. Urinary metabonomics found differences in 31 metabolites between these two groups, including differences in nucleic acids and amino acids. Pathway analysis based on overlapping metabolites showed that pathways of energy and amino acid metabolism, as well as the pentose phosphate pathway, were closely associated with pathological processes in NAFLD and NASH.CONCLUSION These findings suggested that a panel of biomarkers could distinguish between NAFLD and NASH, and could help to determine the molecular mechanism involved in the process of developing NASH from NAFLD. Urinary biomarkers may be diagnostic in these patients and could be used to assess responses to therapeutic interventions. 展开更多
关键词 尿 metabonomics 不含酒精的脂肪肝疾病 STEATOHEPATITIS
下载PDF
Therapeutic mechanism of Yīn-Chén-Hāo decoction in hepatic diseases 被引量:6
2
作者 Jian-Yuan Li Hong-Yan Cao +6 位作者 Lin Sun Run-Fei Sun Chao Wu yan-qin bian Shu Dong Ping Liu Ming-Yu Sun 《World Journal of Gastroenterology》 SCIE CAS 2017年第7期1125-1138,共15页
Yīn-Chén-Hāo decoction(YCHD) is a traditional Chinese medicine formula composed of capillaris(Artemisia capillaris), gardenia(Gardenia jasminoides), and rhubarb(Rheum rhabarbarum) that is used for the treatment... Yīn-Chén-Hāo decoction(YCHD) is a traditional Chinese medicine formula composed of capillaris(Artemisia capillaris), gardenia(Gardenia jasminoides), and rhubarb(Rheum rhabarbarum) that is used for the treatment of damp-heat jaundice. In modern clinics, YCHD is mostly used for hepatic diseases. This review summarizes the biological activities of YCHD and its medical applications. The main active compounds of YCHD are chlorogenic acid, rhein, geniposide, emodin, and scoparone. The pharmacological actions of YCHD include inhibition of hepatic steatosis, apoptosis, necrosis, anti-inflammation, and immune regulation. YCHD could be developed as a new therapeutic strategy for the treatment of hepatic diseases. 展开更多
关键词 Yīn-Chén-Hāo decoction Hepatic disease Clinical application Effector mechanism Review
全文增补中
上一页 1 下一页 到第
使用帮助 返回顶部